In advanced malignant PEComa, perivascular epithelioid cells grow out of control. FYARRO is thought to block one of the signals in the cancer cells that are causing it to grow out of control, helping to stop cancer from growing or spreading.
FYARRO is not a chemotherapy treatment. It is known as a targeted cancer treatment.
In advanced malignant PEComa, perivascular epithelioid cells grow out of control. FYARRO is thought to block one of the signals in the cancer cells that are causing it to grow out of control, helping to stop cancer from growing or spreading.
FYARRO is not a chemotherapy treatment. It is known as a targeted cancer treatment.
mTOR (short for mechanistic target of rapamycin) is a type of protein inside cells called a kinase. A kinase is like an on/off switch: in healthy cells, mTOR turns growth signals on when they are needed and off when they are not
For a majority of people with advanced malignant PEComa, the mTOR switch does not function correctly and is stuck in the "on" position, allowing the cancer cells to grow out of control
FYARRO is an mTOR inhibitor: a targeted cancer drug that helps turn the mTOR switches off again
FYARRO is different from other mTOR inhibitors because it uses nanoparticle technology. Nanoparticle technology is designed to help FYARRO get more of the drug inside tumors to help turn more mTOR switches off
PEComa=perivascular epithelioid cell tumor.
*FYARRO is not for everyone. Talk to your doctor to see if FYARRO may be right for you.
FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat adults with malignant perivascular epithelioid cell tumors (PEComa) that have spread to other parts of the body (metastatic) or cannot be removed by surgery (locally advanced, unresectable). It is not known if FYARRO is safe and effective in people with severe liver problems or in children.
Do not use FYARRO if you have had a severe allergic reaction to sirolimus or other medications that work similarly to sirolimus (eg, everolimus, temsirolimus), or human albumin.
FYARRO can cause the following serious side effects; depending on the severity, your doctor may decide to decrease your dose or stop treatment with FYARRO:
Before taking FYARRO, tell your doctor if you are breast feeding. It is not known if FYARRO could pass into breast milk and harm your baby. You should not breast feed during treatment with FYARRO and for 2 weeks after the last dose. Tell your doctor about all your medical conditions and the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Using FYARRO with certain other medicines can cause serious side effects. Tell your doctor before you start taking any new medicine. You should not drink grapefruit juice or eat grapefruit during your treatment with FYARRO. It may make the amount of FYARRO in your blood increase to a harmful level.
The most common side effects with FYARRO include the following: mouth ulcers or sores; feeling weak or tired; rash; infection; nausea; swelling of arms, hands, feet, ankles, face, or other parts of the body; diarrhea; body pain; decreased weight and appetite; cough; vomiting; and altered taste.
These are not all the possible side effects of FYARRO. Tell your doctor if you have any side effect that bothers you or does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information.
FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat adults with malignant perivascular epithelioid cell tumors (PEComa) that have spread to other parts of the body (metastatic) or cannot be removed by surgery (locally advanced, unresectable). It is not known if FYARRO is safe and effective in people with severe liver problems or in children.
Do not use FYARRO if you have had a severe allergic reaction to sirolimus or other medications that work similarly to sirolimus (eg, everolimus, temsirolimus), or human albumin.
FYARRO can cause the following serious side effects; depending on the severity, your doctor may decide to decrease your dose or stop treatment with FYARRO:
Before taking FYARRO, tell your doctor if you are breast feeding. It is not known if FYARRO could pass into breast milk and harm your baby. You should not breast feed during treatment with FYARRO and for 2 weeks after the last dose. Tell your doctor about all your medical conditions and the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Using FYARRO with certain other medicines can cause serious side effects. Tell your doctor before you start taking any new medicine. You should not drink grapefruit juice or eat grapefruit during your treatment with FYARRO. It may make the amount of FYARRO in your blood increase to a harmful level.
The most common side effects with FYARRO include the following: mouth ulcers or sores; feeling weak or tired; rash; infection; nausea; swelling of arms, hands, feet, ankles, face, or other parts of the body; diarrhea; body pain; decreased weight and appetite; cough; vomiting; and altered taste.
These are not all the possible side effects of FYARRO. Tell your doctor if you have any side effect that bothers you or does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat adults with malignant perivascular epithelioid cell tumors (PEComa) that have spread to other parts of the body (metastatic) or cannot be removed by surgery (locally advanced, unresectable). It is not known if FYARRO is safe and effective in people with severe liver problems or in children.
